UNSPSC 51262101: Atiprosin

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C20H29N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, ALS52889WF chemically known as pyrazino(2',3':3,4)pyrido(1,2-a)indole, 1-ethyl-1,2,3,4,4a,5,6,12b-octahydro-12-methyl-4-(1-methylethyl)-, trans, (z)-2-butenedioate but generally known as atiprosin, which bears US NIH Compound Identifier 3034029. European Medicines Agency schedules Atiprosin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05596MIG.

UNSPSC 51262101 Atiprosin is a Commodity code that captures pharmaceutical products for emergency response and harm reduction, based on state and local solicitation activity that centers on naloxone procurement and related drug-intervention systems. State and local governments use this code to source life-saving medications and deactivation tools for community health programs, emergency medical services, and substance-abuse intervention. The issuing bodies soliciting under the code include county health agencies and state health and human services commissions. Recent activity shows county governments as direct buyers of naloxone inventory for quarterly distribution through community health facilities, while state-level HHS agencies conduct market research on direct-to-manufacturer pharmaceutical contracting models to streamline supply chains and reduce acquisition costs.

Geographic spread across the recent opportunities includes Florida and Texas. Seminole County, Florida issued IFB 60459723LAS in June 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford; the bid closed July 26, 2023, with electronic submission required through the county's e-Procurement Portal. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, as a preliminary market-intelligence exercise exploring vendor capacity for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels, signaling state-level interest in reshaping pharmaceutical procurement strategy before issuing formal competitive solicitations.